Program
sevoloprubart
Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid, led by Eli Lilly.
Furthest: phase 2, since Jan 15, 20243 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 30 open or running | phase 2since Jan 15, 2024 | Sep 8, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2021First study: phase 1 study in HealthyFirst studyNCT05042310 · 94 enrolled · Japan
- Jan 15, 2024Phase 2 study in Multiple SclerosisNCT06220669 · 65 enrolled · United States, France, Italy and more
- Feb 28, 2025Phase 2 study in Arthritis, RheumatoidNCT06859294 · 35 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06859294Arthritis, Rheumatoid · United States | 2 | Terminated | Nov 10, 2025 | 35 |
| NCT06220669Multiple Sclerosis · United States, France, Italy and more | 2 | Terminated | Oct 18, 2025 | 65 |
| NCT05042310Healthy · Japan | 1 | Completed | Dec 27, 2023 | 94 |
How it is read
Names in the registry
- “LY3541860”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.